April 12, 2012 ·
Leave a comment
New press release out today from the offices of Thought Leader Select:
April 12, 2012 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based consulting firm supporting the healthcare industry, is pleased to announce the hiring of Jason Bell as its newest sales executive for the American market.
Bell comes to Thought Leader Select with a solid track record of experience within the biopharmaceutical industry, working as a field hospital representative in support of critical new drug launches in multiple therapeutic areas and disease states, for companies including Allergan, Capellon Pharmaceuticals, and Auriga Pharmaceuticals. In addition to his in-the-field experience and perspective on collaborating with key opinion leaders in medicine to promote effective new treatments, Bell also brings experience gleaned from his time at Clinsys Alterna, a contract research organization (CRO). In his business development role at Clinsys Alterna, Jason consulted with biopharmaceutical industry executives to deliver customized solutions in support of phase I-IV clinical trials.
Jason Bell is a 1997 graduate of California University of Pennsylvania, with a degree in psychology.
“I’m already enjoying my work, speaking with clients and prospective clients about their needs for medical marketing and medical science outreach to health care professionals,” stated Bell. “This company is a great match for my experience and the skills I developed in pharma, CROs, and talent management organizations serving life science ... read more »
March 17, 2011 ·
Leave a comment
Industry Insights from Paul Meade, M.Sc., MPH
The Physician Payment Sunshine Provision is a part of the Patient Protection and Affordable Care Act passed by the U. S. Congress in March of last year. The provision will go into effect on January 1, 2012. Many people in the healthcare industry are struggling to determine if this provision is a good thing or a bad one. Truth be told, it is a bit of both—good, in that it ensures complete transparency among health care providers and manufacturers of pharmaceuticals and medical devices, and bad, because it may expose the benefits some healthcare professionals gain from interacting with some manufacturers.
For years, healthcare professionals have been interacting with manufacturers in many ways; when providers offer their professional services, they expect and receive compensation for their time and knowledge, as would experts in any other industry. Every industry has its experts, and healthcare is no exception. There are healthcare experts in a variety of functional areas and in all therapeutic areas. These experts have medical information and knowledge that is valuable to healthcare manufacturers as they develop and commercialize their products and services. Acting as consultants to industry manufacturers, experts offer guidance in the development of new products, from determining unmet medical needs to suggestions on how to price new products.
Is it fair to compensate ... read more »
May 27, 2010 ·
Leave a comment
Key opinion leaders (KOLs) are health care leaders who make a high-impact footprint while advancing medical science. Thought Leader Select specializes in delivering objective, validated data on the skills and experiences of KOLs, so that pharmaceutical companies can seek their appropriate advice and guidance in the development of new medicines.
Thought Leader Select measures many areas where KOLs leave their respective marks in the medical community, including conducting clinical research studies, publishing articles in leading journals, and presenting breakthrough knowledge at scientific conferences.
In a recent assessment of 57 infectious disease specialists, Thought Leader Select measured the frequency of these global key opinion leaders’ respective participation in advisory boards for the development of new medicines.
Using keywords to link the KOLs with advisory board participation covering a six-year period, Thought Leader Select found that 37 of the 57 physicians had relevant advisory board experience to assist its client company in the development of new antibiotics. Of the 37 physicians with documented advisory board experience, 20 had served on more than four boards in the last few years.
The top decile for the KOL pool averaged participation in nine or more advisory boards during the period of the study.